The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 6, Issue 9, 2007, Pages 2409-2417

  Wickström, Malin ^a,d   Johnsen, John Inge ^b   Ponthan, Frida ^b   Segerström, Lova ^b   Sveinbjörnsson, Baldur ^b   Lindskog, Magnus ^a,b   Lövborg, Henrik ^a,c   Viktorsson, Kristina ^b   Lewensohn, Rolf ^b   Kogner, Per ^b   Larsson, Rolf ^a   Gullbo, Joachim ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; CARBOPLATIN; CASPASE 3; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; J 1; MELPHALAN; PRODRUG; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG INHIBITION; DRUG SCREENING; FEMALE; FLUOROMETRY; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE CHARACTERIZATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELPHALAN; MICE; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PRODRUGS; RATS; RATS, NUDE; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 34748844049     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0156     Document Type: Article

References (28)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Buzdar AU, Legha SS, Blumenschein GR, et al. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer 1982;49:1767-70.
3. Paccagnella A, Tredese F, Salvagno L, et al. Peptichemio in pretreated patients with ovarian cancer. Cancer Treat Rep 1985;69:17-20.
4. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-601.
5. Pastore G, De Bernardi B, Carli M, et al. Peptichemio in neuroblastoma at relapse. Med Pediatr Oncol 1984;12:162-5.
6. Gullbo J, Dhar S, Luthman K, et al. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p- L-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs 2003;14:617-24.
7. Gullbo J, Tullberg M, Vabeno J, et al. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res2003;14:113-32.
8. Gullbo J, Lindhagen E, Bashir-Hassan S, et al. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p- L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs 2004;22:411-20.
9. Gullbo J, Wickstrom M, Tullberg M, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target 2003;11:355-63.
10. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 2002;8:3747-54.
11. Suganuma T, Ino K, Shibata K, et al. Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab Invest 2004;84:639-48.
12. Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Aminopeptidase activities in breast cancer tissue. Clin Chem 1999;45:1797-802.
13. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177-85.
14. Rickardson L, Fryknas M, Haglund C, et al. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006;58:749-58.
15. Lovborg H, Nygren P, Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther 2004;3:521-6.
16. Ponthan F, Johnsen JI, Klevenvall L, Castro J, Kogner P. The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo. Int J Cancer 2003;104:418-24.
17. Ponthan F, Wickstrom M, Gleissman H, et al. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007;13:1036-44.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Scornik OA, Botbol V. Bestatin as an experimental tool in mammals. Curr Drug Metab 2001;2:67-85.
20. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348-57.
21. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997;33:2126-9.
22. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-9.
23. Valteau-Couanet D, Vassal G, Pondarre C, et al. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. Bone Marrow Transplant 1996;17:485-9.
24. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88:734-41.
25. Fukasawa K, Fujii H, Saitoh Y, et al. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett 2006;243:135-43.
26. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82.
27. Quon CY, Stampfli HF. Biochemical properties of blood esmolol esterase. Drug Metab Dispos 1985;13:420-4.
28. Morton CL, Iacono L, Hyatt JL, et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56:629-36.